Cancer Immunotherapy: More Is (Much) Better.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26019173.
- Also identified by DOI 10.1158/1078-0432.CCR-15-0996.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although antibodies against EGFR and HER2 are used to treat cancer, only some patients respond and resistance often emerges. Jacobsen and colleagues present in this issue experimental evidence favoring replacement of the currently applied monoclonal antibodies with oligoclonal mixtures of six synergistic antibodies, simultaneously engaging EGFR, HER2, and also HER3.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- ErbB Receptors
- Erb-b2 Receptor Tyrosine Kinases
- Receptor, ErbB-3